vorinostat has been researched along with Carcinoma, Small Cell Lung in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Triple combinations with a low dosage of cisplatin demonstrate similar therapeutic effects." | 1.43 | Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. ( Chang, YF; Ko, JC; Lee, MS; Liang, MC; Liang, SK; Pan, CH; Wen, BC, 2016) |
| "However, it has been reported that non-small cell lung cancer (NSCLC) is resistant to HDACIs." | 1.35 | Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. ( An, S; Bae, S; Cha, HJ; Jin, YW; Jung, JH; Lee, EM; Lee, SJ; Lee, SM; Park, IC; Shin, S; Yoon, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YQ | 1 |
| Fan, F | 1 |
| Wang, YR | 1 |
| Li, LY | 1 |
| Cao, YJ | 1 |
| Gu, SM | 1 |
| Liu, SS | 1 |
| Zhang, Y | 1 |
| Wang, J | 1 |
| Tie, L | 1 |
| Pan, Y | 1 |
| Li, HF | 1 |
| Li, XJ | 1 |
| Nakajima, W | 1 |
| Sharma, K | 1 |
| Hicks, MA | 1 |
| Le, N | 1 |
| Brown, R | 1 |
| Krystal, GW | 1 |
| Harada, H | 1 |
| Pan, CH | 1 |
| Chang, YF | 1 |
| Lee, MS | 1 |
| Wen, BC | 1 |
| Ko, JC | 1 |
| Liang, SK | 1 |
| Liang, MC | 1 |
| Lee, EM | 1 |
| Shin, S | 1 |
| Cha, HJ | 1 |
| Yoon, Y | 1 |
| Bae, S | 1 |
| Jung, JH | 1 |
| Lee, SM | 1 |
| Lee, SJ | 1 |
| Park, IC | 1 |
| Jin, YW | 1 |
| An, S | 1 |
| Bruzzese, F | 1 |
| Rocco, M | 1 |
| Castelli, S | 1 |
| Di Gennaro, E | 1 |
| Desideri, A | 1 |
| Budillon, A | 1 |
| Gray, J | 1 |
| Cubitt, CL | 1 |
| Zhang, S | 1 |
| Chiappori, A | 1 |
6 other studies available for vorinostat and Carcinoma, Small Cell Lung
| Article | Year |
|---|---|
The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer.
Topics: Animals; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Nude; | 2023 |
Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
Topics: Aniline Compounds; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Cell Line, | 2016 |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; D | 2016 |
Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neop | 2009 |
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumo | 2009 |
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Topics: Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Histone Deace | 2012 |